Evidence map›Paper›PMID 33860882›Full record

ArticleEndocrine2021

Individuals with isolated congenital GH deficiency due to a GHRH receptor gene mutation appear to cope better with SARS-CoV-2 infection than controls.

Manuela A Melo, Lysandro P Borges, Roberto Salvatori, Daniela R V Souza, Hertz T Santos-Júnior, José M de R Neto, Viviane C Campos, Aryanne A Santos, Carla R P Oliveira, Grazielly B da Invenção and 13 more

Abstract read
In one paragraph

Article in Endocrine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Growth hormone - releasing hormone in the immune system.Reviews in endocrine & metabolic disorders · 2025
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Somatotropic Axis, Pace of Life and Aging.Frontiers in endocrinology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Manuela A Melo *Division of Endocrinology, Health Sciences Graduate Program, Aracaju, Brazil.
Lysandro P Borges *Laboratory of Biochemistry and Clinical Immunology, Aracaju, Brazil.
Roberto SalvatoriDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA. salvator@jhmi.edu.ORCID http://orcid.org/0000-0001-6495-2244
Daniela R V SouzaLaboratory of Biochemistry and Clinical Immunology, Aracaju, Brazil.
Hertz T Santos-JúniorDivision of Endocrinology, Health Sciences Graduate Program, Aracaju, Brazil.
José M de R NetoLaboratory of Biochemistry and Clinical Immunology, Aracaju, Brazil.
Viviane C CamposDivision of Endocrinology, Health Sciences Graduate Program, Aracaju, Brazil.
Aryanne A SantosLaboratory of Biochemistry and Clinical Immunology, Aracaju, Brazil.
Carla R P OliveiraDivision of Endocrinology, Health Sciences Graduate Program, Aracaju, Brazil.
Grazielly B da InvençãoLaboratory of Biochemistry and Clinical Immunology, Aracaju, Brazil.
Vanderlan O BatistaDivision of Endocrinology, Health Sciences Graduate Program, Aracaju, Brazil.
Igor L S MatosLaboratory of Biochemistry and Clinical Immunology, Aracaju, Brazil.
Cynthia S Barros-OliveiraDivision of Endocrinology, Health Sciences Graduate Program, Aracaju, Brazil.
Kezia A Dos SantosLaboratory of Biochemistry and Clinical Immunology, Aracaju, Brazil.
Elenilde G SantosDivision of Endocrinology, Health Sciences Graduate Program, Aracaju, Brazil.
Nicolas A A SouzaLaboratory of Biochemistry and Clinical Immunology, Aracaju, Brazil.
Enaldo V MeloDivision of Endocrinology, Health Sciences Graduate Program, Aracaju, Brazil.
Pamela C BorgesLaboratory of Biochemistry and Clinical Immunology, Aracaju, Brazil.
Saulo E F S SantosDivision of Endocrinology, Health Sciences Graduate Program, Aracaju, Brazil.
Brenda M de OliveiraLaboratory of Biochemistry and Clinical Immunology, Aracaju, Brazil.
Alécia A Oliveira-SantosDivision of Endocrinology, Health Sciences Graduate Program, Aracaju, Brazil.
Amélia R de JesusDivision of Immunology, Health Sciences Graduate Program Federal University of Sergipe, Aracaju, 49060-100, Sergipe, Brazil.
Manuel H Aguiar-OliveiraDivision of Endocrinology, Health Sciences Graduate Program, Aracaju, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSeveral interactions exist between the GH/IGF axis and the immune system, including effects on innate immunity and humoral and cellular response. Acquired GH deficiency (GHD) has been recently proposed as a risk factor for severity of COVID-19 infections. However, acquired GHD is often associated to other factors, including pituitary tumors, surgery, radiotherapy, and additional pituitary hormones deficits and their replacements, which, together, may hinder an accurate analysis of the relationship between GHD and COVID-19. Therefore, we decided to assess the seroprevalence of SARS-CoV-2 antibodies and the frequency of symptomatic cases of COVID-19 in adults subjects with untreated isolated GHD (IGHD) due to a homozygous null mutation in the GHRH receptor gene.

methodsA cross-sectional study was carried out in 27 adult IGHD subjects and 27 age- and gender-matched local controls. Interview, physical examination, bio-impedance, hematological and SARS-CoV-2 IgM and IgG antibodies were analyzed.

resultsThere was no difference in the prevalence of positivity of anti-SARS-CoV-2 IgM and IgG antibodies between the two groups. Conversely, no IGHD individual had a previous clinical diagnosis of COVID-19 infection, while 6 control subjects did (p = 0.023).

conclusionThe production of anti-SARS-CoV-2 antibodies was similar between IGHD subjects due to a GHRH receptor gene mutation and controls, but the evolution to symptomatic stages of the infection and the frequency of confirmed cases was lower in IGHD subjects than in GH sufficient individuals.

Indexed as

COVID-19Human Growth HormoneAdultCross-Sectional StudiesHumansMutationReceptors, NeuropeptideReceptors, Pituitary Hormone-Regulating HormoneSARS-CoV-2Seroepidemiologic StudiesHuman Growth HormoneReceptors, NeuropeptideReceptors, Pituitary Hormone-Regulating Hormonesomatotropin releasing hormone receptorCOVID-19GHGHRH receptorIGF-ISARS-CoV-2

Identifiers

PMID33860882
PMCPMC8050633

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.